HF
ACAD icon

HRT Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

HRT Financial’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.31M Buy
+209,929
New +$4.62M 0.01% 1117
2025
Q4 		– Sell
-40,070
Closed -$855K – 3099
2025
Q3 		$855K Buy
+40,070
New +$948K ﹤0.01% 1609
2025
Q1 		– Sell
-92,926
Closed -$1.71M – 2443
2024
Q4 		$1.71M Buy
92,926
+40,558
+77% +$655K 0.01% 811
2024
Q3 		$805K Sell
52,368
-123,451
-70% -$2.06M ﹤0.01% 1358
2024
Q2 		$2.86M Buy
175,819
+141,756
+416% +$2.29M 0.02% 598
2024
Q1 		$629K Sell
34,063
-276,499
-89% -$6.85M ﹤0.01% 1138
2023
Q4 		$9.72M Buy
310,562
+281,165
+956% +$6.71M 0.07% 165
2023
Q3 		$612K Buy
+29,397
New +$798K 0.01% 1287
2023
Q2 		– Sell
-257,237
Closed -$4.84M – 2362
2023
Q1 		$4.84M Buy
+257,237
New +$4.9M 0.06% 264
2022
Q3 		– Sell
-55,918
Closed -$787K – 2707
2022
Q2 		$787K Buy
55,918
+14,020
+33% +$262K 0.01% 1095
2022
Q1 		$1.01M Sell
41,898
-92,531
-69% -$2.24M 0.01% 1013
2021
Q4 		$3.14M Buy
+134,429
New +$2.7M 0.02% 448
2020
Q4 		– Sell
-65,259
Closed -$2.69M – 1775
2020
Q3 		$2.69M Sell
65,259
-29,948
-31% -$1.29M 0.08% 173
2020
Q2 		$4.61M Buy
+95,207
New +$4.57M 0.14% 138

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HRT Financial's ACAD Position: Q2 2026 in Review

HRT Financial opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 209,929 shares worth $5.31M. The stake represents 0.01% of the portfolio and ranks #1117 among its holdings. This is a return to the name: HRT Financial previously reported a position in ACAD as recently as Q3 2025.

HRT Financial first reported a position in ACAD in Q2 2020 and has held it in 14 quarters since. The position peaked at $9.72M in Q4 2023. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • HRT Financial held 209,929 shares of Acadia Pharmaceuticals worth $5.31M as of Q2 2026.
  • Acadia Pharmaceuticals was a new HRT Financial position in Q2 2026.
  • Acadia Pharmaceuticals made up 0.01% of HRT Financial's portfolio in Q2 2026, its #1117 holding.
  • HRT Financial first reported a position in Acadia Pharmaceuticals in Q2 2020 and has held it in 14 quarters since.
  • HRT Financial's Acadia Pharmaceuticals position peaked at $9.72M in Q4 2023.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.